Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski Sells 8,287 Shares

Exelixis, Inc. (NASDAQ:EXELGet Free Report) Director Jack L. Wyszomierski sold 8,287 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the sale, the director now owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Exelixis Trading Up 1.0 %

EXEL traded up $0.22 during trading on Thursday, hitting $22.18. The stock had a trading volume of 1,393,084 shares, compared to its average volume of 2,226,625. The firm has a market cap of $6.72 billion, a PE ratio of 34.66, a P/E/G ratio of 0.53 and a beta of 0.56. Exelixis, Inc. has a 12 month low of $18.64 and a 12 month high of $24.34. The company has a 50 day simple moving average of $22.22 and a 200-day simple moving average of $22.30.

Exelixis (NASDAQ:EXELGet Free Report) last announced its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.16). The firm had revenue of $425.23 million during the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business’s revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.12 EPS. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EXEL. Fisher Asset Management LLC raised its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares during the period. Contravisory Investment Management Inc. bought a new position in shares of Exelixis during the 4th quarter worth about $26,000. GAMMA Investing LLC bought a new position in shares of Exelixis during the 4th quarter worth about $27,000. Rise Advisors LLC bought a new position in shares of Exelixis during the 1st quarter worth about $28,000. Finally, USA Financial Formulas increased its holdings in shares of Exelixis by 1,548.0% during the 4th quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,935 shares during the period. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. StockNews.com downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Barclays lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a research note on Thursday, April 11th. Stephens started coverage on shares of Exelixis in a research note on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Exelixis in a research note on Friday, May 3rd. Finally, JMP Securities reissued a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a research note on Wednesday, April 10th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.13.

Get Our Latest Stock Report on Exelixis

About Exelixis

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Featured Articles

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.